Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor

Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases plasma low-density lipoprotein cholesterol (LDL-C) by decreasing expression of the LDL receptor on hepatic cells. Evolocumab is a human monoclonal immunoglobulin G2 that binds specifically to human PCSK9 to reduce LDL-C. Evolocumab exhi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kasichayanula, Sreeneeranj, Grover, Anita, Emery, Maurice G., Gibbs, Megan A., Somaratne, Ransi, Wasserman, Scott M., Gibbs, John P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999140/
https://www.ncbi.nlm.nih.gov/pubmed/29353350
http://dx.doi.org/10.1007/s40262-017-0620-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999140/
https://www.ncbi.nlm.nih.gov/pubmed/29353350
http://dx.doi.org/10.1007/s40262-017-0620-7

Ejemplares similares